Faster clearance of mirodenafil in rats with acute renal failure induced by uranyl nitrate: Contribution of increased protein expression of hepatic CYP3A1 and intestinal CYP1A1 and 3A1/2

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 10, 2009, Pages 1325-1332

  Choi, Young H ^a   Lee, Young S ^a   Kim, Tae K ^b   Lee, Bong Y ^b   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

^b SK Chemicals   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 2D1; CYTOCHROME P450 3A1; CYTOCHROME P450 3A2; MIRODENAFIL; PHOSPHODIESTERASE V INHIBITOR; SK 3541; UNCLASSIFIED DRUG; URANYL NITRATE; CYP3A1 PROTEIN, RAT; N DEHYDROXYETHYLMIRODENAFIL; N-DEHYDROXYETHYLMIRODENAFIL; PYRIMIDINONE DERIVATIVE; SULFONAMIDE; UNSPECIFIC MONOOXYGENASE;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; LIVER MICROSOME; MALE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; RAT; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; INTESTINE; INTRAVENOUS DRUG ADMINISTRATION; LIVER; METABOLISM; MICROSOME; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A1; DISEASE MODELS, ANIMAL; INJECTIONS, INTRAVENOUS; INTESTINES; KIDNEY FAILURE, ACUTE; LIVER; MALE; MICROSOMES; PYRIMIDINONES; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES; URANYL NITRATE;

EID: 85047681160     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.61.10.0008     Document Type: Article

References (22)

1. Lincoln TM. Cyclic GMP and phosphodiesterase 5 inhibitor therapies: what's on the horizon? Mol Pharmacol 2004; 66: 776-784.
2. Aversa A et al. Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction. Curr Pharm Res 2006; 12: 3467-3484.
3. Broderick GA. Oral pharmacotherapy and the contemporary evaluation and management of erectile dysfunction. Rev Urol 2003; 5: S9-S20.
4. Lee J et al. Metabolism and excretion of 5-ethyl-2-{5-[4-(2- hydroxyethyl)piperazine-1-sulfonyl]-2-propoxy-phenyl}-7-propyl-3, 5-dihydropyrrolo[3,2-d]-pyrimidin-4-one (SK3530) in rats. Rapid Commun Mass Spectrum 2007; 21: 1139-1149.
5. Choi YH et al. Dose-dependent pharmacokinetics, hepatic and gastrointestinal first-pass effects, and hepatic CYP isozymes responsible for metabolism of mirodenafil, a new erectogenic, in rats: involvement of CYP1A1/2, 2B1/2, 2D1, and 3A1/2. Presented in 2008 Annual Convention of the Pharmaceutical Society of Korea, International Convention Center, Jeju, South Korea, April 30-May 4, 2008.
6. Moon YJ et al. Effects of acute renal failure on the pharmacokinetics of chlorozoxazone in rats. Drug Metab Dispos 2003; 31: 776-784.
7. Lee DY et al. Faster clearance of omeprazole in rats with acute renal failure induced by uranyl nitrate: induction of hepatic CYP3A1 and intestinal CYP1A and 3A expressions. J Pharm Pharmacol 2009 (in press).
8. Dachille G et al. Sexual dysfunction in patients under dialytic treatment. Minerva. Urol Nefrol 2006; 58: 195-200.
9. Kim SH et al. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 1993; 21: 1-17.
10. Choi YH et al. Simultaneous LC-UV analysis of mirodenafil and its two main metabolites in rat plasma and urine, and in tissue homogenates. Chromatographia 2009; 69: 677-683.
11. Choi YH et al. Dose-independent pharmacokinetics of metformin in rats: hepatic and gastrointestinal first-pass effects. J Pharm Sci 2006; 95: 2543-2552.
12. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
13. Duggleby RG. Analysis of enzyme progress curves by nonlinear regression. Methods Enzymol 1995; 249: 61-90.
14. Gibaldi M, Perrier D. Pharmacokinetics, 2nd edn. New York: Marcel-Dekker, 1982.
15. Chiou WL. Critical evaluation of the potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 1978; 6: 539-546.
16. Choi YH et al. Slower clearance of intravenous metformin in rats with acute renal failure induced by uranyl nitrate: Contribution of slower renal and non-renal clearances. Eur J Pharm Sci 2009 (in press).
17. Wilkinson GR, Shand DG. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975; 18: 377-390.
18. Lee MG, Chiou WL. Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. J Pharmacokinet Biopharm 1983; 11: 623-640.
19. Kaminsky LS, Fasco MJ. Small intestinal cytochromes P450. Crit Rev Toxicol 1991; 21: 407-422.
20. Lindell M et al. Expression of genes encoding for drug metabolising cytochrome P450 enzymes and P-glycoprotein in the rat small intestine: comparison to the liver. Eur J Drug Metab Pharmacokinet 2003; 28: 41-48.
21. Martignoni M et al. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2006; 2: 875-894.
22. Lewis DFV. Cytochrome P450: Structure, Function, and Mechanism. London: Taylor & Fancis, 1996.